Zoetis falls after trimming full-year forecast, Q1 miss
** Shares of animal healthcare company Zoetis ZTS.N fall 7.4% to $102.94 premarket ** Cuts annual profit forecast to $6.85-$7.00 per share from $7.00-$7.10 per share ** Reports Q1 adj profit of $1.53/share, below analysts' estimate of $1.61/share – LSEG data ** Posts Q1 revenue of $2.26 bln vs analysts' estimate of $2.31 bln – LSEG data ** As of last close, stock down ~12% (Reporting by Sahil Pandey in Bengaluru) ((Sahil.Pandey@thomsonreuters.com))
Recent news on Zoetis
See all newsBrief: Zoetis Receives FDA Approval For Convenia® Rtu For Dogs (Cefovecin Injectable Suspension), Helping More Medium And Large Dogs Access Single-Injection Treatment
Brief: FDA Approves Ready-To-Use Cefovecin Injectable For Treatment Of Certain Skin Infections In Dogs
U.S. RESEARCH ROUNDUP-Masco, Sherwin-Williams, Vulcan Materials
Zoetis gets US FDA emergency use nod for treatment for screwworm in dogs
Brief: FDA Issues Emergency Use Authorization For Simparica Trio To Treat New World Screwworm In Dogs, Puppies